Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study).
Juan José CastónAngela CanoInés Pérez-CamachoJose M AguadoJordi CarratalaFernando RamascoAlex SorianoVicente PintadoLaura Castelo-CorralAdrian SousaMaría Carmen FariñasPatricia MuñozVicente Abril López De MedranoÓscar Sanz-PeláezIbai Los ArcosIrene Gracia-AhufingerElena Pérez-NadalesElisa VidalAntonio DoblasClara NateraLuis Martínez-MartínezJulian Torre-CisnerosPublished in: The Journal of antimicrobial chemotherapy (2022)
Ceftazidime/avibactam is an effective alternative for the treatment of CPE infections, especially in patients with INCREMENT-CPE scores of >7 points. A randomized controlled trial should confirm these findings.